Key Highlights

  • AOTI, Inc. (LSE:AOTI) shares rose 3.25% on Wednesday, 7 October 2026, on the AIM market of the London Stock Exchange.
  • The US Centers for Medicare and Medicaid Services published a proposed Local Coverage Determination for topical oxygen therapy, which AOTI calls transformational.
  • AOTI holds about a 75% share of the topical oxygen therapy market with its TWO2 therapy.
  • Clinical data show an 88% reduction in hospitalisations and a 71% reduction in amputations over 12 months.
  • Cash stood at about US$13.8 million at 30 June 2026, with interim results scheduled for 30 September.

AOTI, Inc. (LSE:AOTI), the medical technology group focused on durable healing of wounds and the prevention of amputations, gained 3.25% on Wednesday, 7 October 2026, on the AIM market of the London Stock Exchange.

The California-based company, which listed on AIM in 2024, is approaching what could be the most important regulatory milestone in its history: final Medicare coverage for topical oxygen therapy in the United States.

Why AOTI (LSE:AOTI) Shares Are Rising Today

The rise in AOTI (LSE:AOTI) reflects growing anticipation around the finalisation of a proposed Local Coverage Determination (LCD) for topical oxygen therapy. In July 2026, shortly after the end of its first half, AOTI announced that the US Centers for Medicare and Medicaid Services (CMS) had published the proposed LCD.

AOTI described this as a transformational milestone that would dramatically expand the US addressable market and growth potential for its TWO2 therapy. Once finalised, mandated Medicare coverage and reimbursement could significantly widen patient access and help accelerate adoption across Medicaid, commercial insurers and other segments. Investors are now positioning for the final decision, and the interim results published at the end of September have kept the story in focus.

What Makes TWO2 Therapy Different

AOTI's patented, non-invasive Topical Wound Oxygen (TWO2) therapy is the only intermittent topical oxygen wound therapy on the market. It is administered by patients at home, which improves access to care and treatment compliance.

The therapy is primarily used for diabetic foot ulcers, a serious and costly complication of diabetes. Double-blinded randomised controlled trials and real-world evidence studies have shown TWO2 can more durably reduce recurrence, with an 88% reduction in hospitalisations and a 71% reduction in amputations over 12 months. AOTI published a further real-world study in April 2026.

TWO2 has regulatory clearance in the US, Europe, the UK, Canada, China, Australia and Saudi Arabia, and has received positive coverage recommendations from Germany's Federal Joint Committee and the UK's National Institute for Health and Care Excellence.

First-Half 2026 Trading

In its first-half trading update, AOTI confirmed it maintains about a 75% share of the topical oxygen therapy market. Cash stood at approximately US$13.8 million at 30 June 2026, up from US$13.4 million at the end of 2025, suggesting a disciplined approach to spending.

Earlier in 2026, Chief Executive Mike Griffiths said AOTI was well positioned to re-accelerate growth as US healthcare market headwinds abate, and that the company entered the year with a stronger core Business than at any point in its history. Directors have also been buying shares through the company's employee share purchase plan.

Why the Stock Is in Focus and What Investors Are Watching

AOTI is in focus because the Medicare LCD could be a step-change catalyst. Medicare covers a large share of US patients with diabetic foot ulcers, so formal coverage could unlock a much larger addressable market.

Investors are watching the timing and final wording of the LCD, Revenue growth trends, gross margins, Operating Cash Flow and international adoption, particularly in Germany and the UK following positive coverage recommendations. Commentary on how AOTI plans to scale its sales and service capacity to meet potential new Demand will also be important.

Risks to Consider

Proposed coverage decisions can be modified or delayed before finalisation. Reimbursement rates may be lower than hoped. Scaling a home-based therapy service requires Investment in people and logistics. AOTI remains a relatively small company, and its share price can react sharply to regulatory news.

Outlook for AOTI (LSE:AOTI)

AOTI (LSE:AOTI) is approaching a potentially transformational Medicare milestone with strong clinical evidence and a dominant market position. Wednesday's 3.25% gain shows investors are building positions ahead of the final LCD. Confirmation of coverage could reshape the company's growth trajectory.